All In Biotech

Drug Trial Radar · NCT00894699

A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTabs™ in Patients Undergoing an Elective Abdominal Liposuction Procedure

Last checked: Nov 20, 2026Latest source record: Jun 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

40

Actual

Start

Jun 2009

Primary completion

Sep 2009

Study completion Sep 2009

Sponsor

Lead sponsor
Talphera, IncIndustry
Sponsor type
Industry
First posted
May 7, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and effectiveness of a study medication that contains a combination of a pain medication, sufentanil, and a sedative, triazolam. This drug is being designed to provide mild sedation as well as reduce anxiety and pain before and during a procedure (in this case elective abdominal liposuction).

Conditions

  • Sedation
  • Anxiety
  • Pain

Interventions

  • Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)Drug

    Single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™

  • Placebo NanoTab™Drug

    Single dose of sublingual placebo NanoTab™

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Summed Richmond Agitation Sedation Score (RASS) Over the 4-hour Study Period (SRS-4)Time frame: 4 hour study period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lotus Clinical Research, Inc.

    Pasadena, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.